



2026/2006

24.9.2026

DECISION OF THE EEA JOINT COMMITTEE No 171/2026

of 5 June 2026

**amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement
[2026/2006]**

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ("the EEA Agreement"), and in particular Article 98 thereof,

Whereas:

- (1) Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 renewing the approval of the active substance spinosad in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 ⁽¹⁾, as corrected by OJ L, 2026/90291, 17.4.2026, is to be incorporated into the EEA Agreement.
- (2) Commission Implementing Regulation (EU) 2026/355 of 18 February 2026 renewing the approval of the active substance pyrimethanil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 ⁽²⁾ is to be incorporated into the EEA Agreement.
- (3) Commission Implementing Regulation (EU) 2026/398 of 18 February 2026 amending Implementing Regulation (EU) No 686/2012 as regards the allocation to Member States, for the purposes of the renewal procedure, of the evaluation of metconazole and quinolin-8-ol ⁽³⁾ is to be incorporated into the EEA Agreement.
- (4) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XV of Annex II to the EEA Agreement is amended as follows:

1. The following indents are added in point 13a (Commission Implementing Regulation (EU) No 540/2011):
 - **32026 R 0351:** Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 (OJ L, 2026/351, 19.2.2026), as corrected by OJ L, 2026/90291, 17.4.2026,
 - **32026 R 0355:** Commission Implementing Regulation (EU) 2026/355 of 18 February 2026 (OJ L, 2026/355, 19.2.2026).'
2. The following points are inserted after point 13zzzzzzzzzzzzzzzzr (Commission Implementing Regulation (EU) 2026/312):
 - '13zzzzzzzzzzzzzzzs. **32026 R 0351:** Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 renewing the approval of the active substance spinosad in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L, 2026/351, 19.2.2026), as corrected by OJ L, 2026/90291, 17.4.2026.
 - 13zzzzzzzzzzzzzzzt. **32026 R 0355:** Commission Implementing Regulation (EU) 2026/355 of 18 February 2026 renewing the approval of the active substance pyrimethanil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L, 2026/355, 19.2.2026).'

⁽¹⁾ OJ L, 2026/351, 19.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/351/oj.

⁽²⁾ OJ L, 2026/355, 19.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/355/oj.

⁽³⁾ OJ L, 2026/398, 19.2.2026, ELI: http://data.europa.eu/eli/reg_impl/2026/398/oj.

3. The following indent is added in point 13zzze (Commission Implementing Regulation (EU) No 686/2012):
- ‘— **32026 R 0398**: Commission Implementing Regulation (EU) 2026/398 of 18 February 2026 (OJ L, 2026/398, 19.2.2026).’

Article 2

The texts of Implementing Regulations (EU) 2026/351, as corrected by OJ L, 2026/90291, 17.4.2026, (EU) 2026/355 and (EU) 2026/398 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 6 June 2026, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 5 June 2026.

For the EEA Joint Committee
The President
Nicolas VON LINGEN

(*) No constitutional requirements indicated.